In conclusion, low IGFBP7 gene expression identifies a subset of breast cancer patients for whom the addition of ganitumab/metformin to neoadjuvant chemotherapy results in a significantly improved pCR rate compared to neoadjuvant chemotherapy alone. Here, IGFBP7 is linked to breast cancer.